Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028661 | 0.78 | CA1 (0.33) | KAT6AKAT5KAT8DDB1CRBN | |
| SCHEMBL25941872 | 0.77 | SLC6A9 (0.32) | KAT6AKAT5KAT8SLC6A9DDB1 | |
| Hydrochloric Acid SCHEMBL28056378 | 0.77 | KAT6A (0.33) | KAT6AKAT5KAT8SLC6A9 | |
| SCHEMBL15454478 | 0.74 | SLC6A9 (0.35) | SLC6A9 | |
| SCHEMBL15454860 | 0.74 | ADORA2A (0.30) | — | |
| SCHEMBL8250024 | 0.71 | HTR6 (0.45) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL25801628 | 0.70 | MEN1 (0.39) | KAT6AKAT5KAT8ALDH1A1 | |
| SCHEMBL14837642 | 0.67 | MAPT (0.41) | SLC6A9ALDH1A1 | |
| SCHEMBL31579019 | 0.67 | P2RX7 (0.51) | DDB1CRBNALDH1A1HSD17B10TDP1 | |
| SCHEMBL2054711 | 0.66 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717266-A2 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250034140-A1 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therpeutics, Inc. (US) | 2025-01-30 | — | — | US | disclosed |
| US-12139486-B2 | Octahydro fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4434584-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-4119561-B1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4219494-A1 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219494-A1 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2014140310-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140038926-A1 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | CORCEPT THERAPEUTICS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038926-A1 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | CORCEPT THERAPEUTICS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2575815-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | Albany Molecular Research, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011153359-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | KAT6A 695/4885KAT5 928/4885KAT8 1317/4885 |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | KAT6A 1868/4885KAT5 3041/4885KAT8 3610/4885 |
| US-20250034140-A1 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | KAT6A 381/4885KAT5 1021/4885KAT8 900/4885 |
| US-20140038926-A1 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | NR3C1, NR3C2, NR5A1 | KAT6A 513/4885KAT5 650/4885KAT8 792/4885 |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | KAT6A 695/4885KAT5 928/4885KAT8 1317/4885 |
| US-20110312931-A1 | GLYCINE TRANSPORTER-1 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC6A5, SLC7A1, AGXT | KAT6A 1603/4885KAT5 3254/4885KAT8 3518/4885 |
| US-12139486-B2 | Octahydro fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | KAT6A 381/4885KAT5 1021/4885KAT8 900/4885 |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | KAT6A 695/4885KAT5 928/4885KAT8 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.